Results 91 to 100 of about 7,115 (194)

Severe Hepatitis Complicating Olmesartan Enteropathy: A Case Report

Case Reports in Gastroenterology
Introduction: Olmesartan, an angiotensin II receptor antagonist, is associated with an uncommon complication of enteropathy that presents insidiously, usually months to years after initial commencement of anti-hypertensive therapy which can be dose ...
Ruyi Tan, Joshua Haron Abasszade, Hardesh Dhillon, Chih Chien Kuan, Thomas Worland, Shireen Tabatabai   +5 more
doaj   +1 more source

ROLE OF BLOOD PRESSURE REDUCTION IN PREVENTION OF CARDIAC AND VASCULAR HYPERTROPHY

Российский кардиологический журнал, 2011
We investigated whether prevention of cardiac and vascular remodelling associated with inhibition of angiotensin II is independent of the blood pressure (BP) lowering action of angiotensin II type 1 (AT1) receptor blockade.
H. Yokoyama, D. B. Averill, K. B. Brosnihan, R. D. Smith, E. L. Schiffrin, C. M. Ferrario   +5 more
doaj  

Bioequivalence Studies in Healthy Volunteers: Olmesartan Medoxomil

, 2011
This study aimed to investigate the bioequivalence of test and reference formulations of 40mg olmesartan medoxomil (CAS 144689-63-4) in 36 healthy male volunteers.
Diler, Z. Irem, Unal, Duri Şehvar, Ozbay, Latif, Erol, Dilek   +3 more
core   +1 more source

Clinical efficacy and safety of olmesartan/hydrochlorothiazide combination therapy in patients with essential hypertension

Vascular Health and Risk Management, 2008
Luis M RuilopeUnidad de Hipertensión, Hospital 12 de Octubre, Madrid, SpainAbstract: Hypertension is a major risk factor for cardiovascular disease that contributes to the premature death of millions of people each year, and identification and ...
Luis M Ruilope
doaj  

PHARMACOECONOMIC ANALYSIS OF OLMESARTAN THERAPY IN THE INDIVIDUAL–LEVEL MANAGEMENT OF ARTERIAL HYPERTENSION

Российский кардиологический журнал, 2012
The pharmacoeconomic analysis compared the strategies of arterial hypertension (AH) management using different angiotensin II receptor blockers (ARB). The first stage of the analysis included the cost-effectiveness modelling in patients with moderate AH ...
S. G. Gorokhova, V. V. Ryazhenov
doaj  

BLOOD PRESSURE-LOWERING EFFICACY OF OLMESARTAN RELATIVE TO OTHER ANGIOTENSIN II RECEPTOR ANTAGONISTS: AN OVERVIEW OF RANDOMIZED CONTROLLED STUDIES

Российский кардиологический журнал, 2010
The aim of the present work was to review published studies, investigating the dose-related efficacy on blood pressure (BP) of olmesartan and of other commercially available angiotensin II type I receptor blockers (ARBs).
Faiez Zannad, Renaud Fay
doaj  

[An unusual case of olmesartan induced enteropathy].

, 2019
Olmesartan induced enteropathy was first described in 2012. It is a rare adverse effect of this antihypertensive drug. The clinical presentation commonly includes severe chronic diarrhea leading to weight loss and a variable degree of dehydration ...
Henry, Paulina, Dano, Hélène, Piessevaux, Hubert, Jouret-Mourin, Anne   +3 more
core   +1 more source

Farmasötik Formlarda Olmesartan Medoksomil, Hidroklorotiyazid Ve Safsızlıkların Yüksek Basınçlı Sıvı Kromatografisi Yöntemiyle Tayini

, 2014
Çalışmamızda antihipertansif etkili ilaç etken maddeleri, Olmesartan medoksomil ve Hidroklorotiyazid ve bu etken maddelerin safsızlıklarının aynı anda tayinleri amacıyla bir Agilent 1100 serisi HPLC yöntemi geliştirilmiş ve valide edilmiştir.
Çağlar SAÇINTI
core   +1 more source

Bioequivalence evaluation of two amlodipine salts, besylate and orotate, each in a fixed-dose combination with olmesartan in healthy subjects

Drug Design, Development and Therapy, 2015
Soo-Yun Lee,1 Jung-Ryul Kim,2,3 Jin Ah Jung,4 Wooseong Huh,2,5 Mi Young Bahng,6 Jae-Wook Ko1,2 1Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Republic of Korea; 2Department of Clinical Pharmacology and ...
Lee SY, Kim JR, Jung JA, Huh W, Bahng MY, Ko JW   +5 more
doaj  

Enteropatía por olmesartán

Galicia Clínica, 2017
El olmesartán es un antagonista de receptores de angiotensina II comúnmente empleado en el tratamiento de la HTA. Desde el año 2012 se han publicado diversos trabajos alertando de su relación con una enteropatía similar al esprúe celíaco.
doaj   +1 more source